Beth N Peshkin
Overview
Explore the profile of Beth N Peshkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
2793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith D, Beyene R, Kolm P, Young T, Zifa S, Natividad V, et al.
Clin Transl Sci
. 2025 Feb;
18(2):e70154.
PMID: 39921243
This trial aimed to identify the effects of providing pharmacogenomic (PGx) results and recommendations for patients with chronic pain treated in primary care practices compared to standard care. An open-label,...
2.
Kilbride M, Peshkin B, Hamilton J, Brower J, Ovadia H, Friedman Ross L, et al.
Public Health Genomics
. 2025 Feb;
28(1):102-112.
PMID: 39908008
Introduction: Despite guidelines discouraging pediatric genetic testing for adult-onset hereditary cancer risk, direct-to-consumer (DTC) companies make them available to children's parents. This study examined the perspectives of high-risk parents toward...
3.
Chaillet K, Sleiman Jr M, Yockel M, Peshkin B, Chiang J, Isaacs C, et al.
Psychol Health Med
. 2024 Oct;
30(2):297-308.
PMID: 39433288
This study aimed to understand long-term coping responses of mothers ( = 287) receiving genetic counseling and testing (GCT) for hereditary breast/ovarian cancer (HBOC) syndrome. Psychological characteristics, including cancer-specific distress...
4.
Grisham C, Peshkin B, Sorgen L, Isaacs C, Ladd M, Jacobs A, et al.
Public Health Genomics
. 2024 Aug;
27(1):100-109.
PMID: 39173603
Introduction: When a pathogenic BRCA1 or BRCA2 mutation is identified in a family, cascade genetic testing of family members is recommended since the results may inform screening or treatment decisions...
5.
Barnes D, Tyrer J, Dennis J, Leslie G, Bolla M, Lush M, et al.
medRxiv
. 2024 Mar;
PMID: 38496424
Background: Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of (CIMBA),...
6.
Schwartz M, Peshkin B, Isaacs C, Grisham C, Holmes N, Sorgen L, et al.
J Natl Compr Canc Netw
. 2023 Dec;
21(12):1261-1268.e14.
PMID: 38081141
Background: Germline genetic testing is recommended for men with metastatic or high-risk prostate cancer to inform treatment and risk management for other cancers and inform genetic testing in at-risk relatives....
7.
Bhatt M, Peshkin B, Kazi S, Schwartz M, Ashai N, Swain S, et al.
Pharmacogenomics
. 2023 Nov;
24(16):859-870.
PMID: 37942634
Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. A questionnaire was designed and disseminated...
8.
Tercyak K, DeMarco T, Schneider K, Luta G, Isaacs C, Garber J, et al.
PEC Innov
. 2023 May;
2:100129.
PMID: 37214493
Objective: Evaluate the impact of a targeted family communication intervention for mothers undergoing genetic counseling and testing (GCT) for gene alterations. Methods: Following GCT, mothers (N = 204; M age...
9.
Bowen A, Gomez-Trillos S, Curran G, Graves K, Sheppard V, Schwartz M, et al.
J Genet Couns
. 2023 Apr;
32(5):965-981.
PMID: 37062905
Genetic counseling and testing (GCT) inform cancer management for persons at risk for hereditary breast and ovarian cancer (HBOC). Community-based organizations (CBOs) may play a role in identifying at-risk Latinx...
10.
Hasser E, Peshkin B, Hamilton J, Brower J, Ovadia H, Friedman Ross L, et al.
J Genet Couns
. 2023 Feb;
32(4):768-777.
PMID: 36748334
Neither direct-to-consumer (DTC) genetic testing nor predictive genetic testing for adult-onset conditions is recommended for minor children due to ethical concerns and low clinical utility. However, parents with pathogenic variants...